AstraZeneca (AZNCF) FDA Approvals

AstraZeneca logo
$187.10 0.00 (0.00%)
As of 11/17/2026

AstraZeneca's Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by AstraZeneca (AZNCF). Over the past two years, AstraZeneca has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Durvalumab, TAGRISSO®, NeXT, casdatifan, and capivasertib. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

Durvalumab FDA Regulatory Timeline and Events

Durvalumab is a drug developed by AstraZeneca for the following indication: Treatment Of Locally Advanced Or Metastatic Biliary Tract Cancer In Combination With Chemotherapy. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

TAGRISSO® (osimertinib) FDA Regulatory Events

TAGRISSO® (osimertinib) is a drug developed by AstraZeneca for the following indication: Third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

NeXT Personal FDA Regulatory Events

NeXT Personal is a drug developed by AstraZeneca for the following indication: in patients with unresectable stage III, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Casdatifan FDA Regulatory Events

Casdatifan is a drug developed by AstraZeneca for the following indication: In patients with ccRCC. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Capivasertib FDA Regulatory Events

Capivasertib is a drug developed by AstraZeneca for the following indication: In patients with locally advanced (inoperable) or metastatic triple-negative breast cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

AstraZeneca FDA Events - Frequently Asked Questions

In the past two years, AstraZeneca (AZNCF) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, AstraZeneca (AZNCF) has reported FDA regulatory activity for the following drugs: Durvalumab, TAGRISSO® (osimertinib), NeXT Personal, casdatifan and capivasertib.

The most recent FDA-related event for AstraZeneca occurred on November 13, 2026, involving Durvalumab. The update was categorized as "Approved," with the company reporting: "AstraZeneca’s ​IMFINZI® (durvalumab)​ in combination with enfortumab vedotin-ejfv (EV) as neoadjuvant treatment, followed by IMFINZI monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy."

Current therapies from AstraZeneca in review with the FDA target conditions such as:

  • Treatment Of Locally Advanced Or Metastatic Biliary Tract Cancer In Combination With Chemotherapy - Durvalumab
  • Third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. - TAGRISSO® (osimertinib)
  • in patients with unresectable stage III, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). - NeXT Personal
  • In patients with ccRCC - casdatifan
  • In patients with locally advanced (inoperable) or metastatic triple-negative breast cancer - capivasertib
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for OTCMKTS:AZNCF last updated on 11/16/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners